Our Pipeline
We are currently advancing a pipeline of drug candidates, all discovered in-house, to address rare conditions with significant unmet need and cancer.
Program
Preclinical
Phase 1
Phase 2
Phase 3
Program Highlights
Aldafermin in Primary Sclerosing Cholangitis
NGM120 in Hyperemesis Gravidarum
NGM707 in Advanced Solid Tumors
Partner with NGM in our Mission
Partnering has always played a key role in extending the potential of our Biologics Discovery Engine across multiple therapeutic areas. We have a strong track record of collaborations with leading pharmaceutical companies including Merck, Janssen, Daiichi-Sankyo and MedImmune (AstraZeneca).
We seek strategic partners who share our passion for innovation, our commitment to scientific excellence, and our mission to deliver life-changing medicines for patients.